{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:53:44Z","timestamp":1778756024727,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10147-022-02189-7","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T16:02:59Z","timestamp":1654099379000},"page":"1364-1371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+\u2009and CD8+\u2009T cells in Japanese melanoma patients"],"prefix":"10.1007","volume":"27","author":[{"given":"Daisuke","family":"Yoneta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Minowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokimasa","family":"Hida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5391-3397","authenticated-orcid":false,"given":"Hisashi","family":"Uhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2189_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"28","author":"J Madore","year":"2015","unstructured":"Madore J, Vilain RE, Menzies AM et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1\/PD-L1 clinical trials. Pigment Cell Melanoma Res 28:245\u2013253. https:\/\/doi.org\/10.1111\/pcmr.12340","journal-title":"Pigment Cell Melanoma Res"},{"key":"2189_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","volume":"100","author":"S Gandini","year":"2016","unstructured":"Gandini S, Massi D, Mandal\u00e0 M (2016) PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 100:88\u201398. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.02.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"2189_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.humpath.2017.06.012","volume":"66","author":"N Frydenlund","year":"2017","unstructured":"Frydenlund N, Mahalingam M (2017) PD-L1 and immune escape: Insights from melanoma and other lineage-unrelated malignancies. Hum Pathol 66:13\u201333. https:\/\/doi.org\/10.1016\/j.humpath.2017.06.012","journal-title":"Hum Pathol"},{"issue":"18","key":"2189_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000006369","volume":"96","author":"Q Wang","year":"2017","unstructured":"Wang Q, Liu F, Liu L (2017) Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore) 96(18):e6369. https:\/\/doi.org\/10.1097\/md.0000000000006369","journal-title":"Medicine (Baltimore)"},{"key":"2189_CR5","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1038\/s41598-017-04023-x","volume":"7","author":"S Xue","year":"2017","unstructured":"Xue S, Song G, Yu J (2017) The prognostic significance of PD-L1 expression in patients with glioma: a meta-analysis. Sci Rep 7:4231. https:\/\/doi.org\/10.1038\/s41598-017-04023-x","journal-title":"Sci Rep"},{"key":"2189_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131403","volume":"10","author":"P Wu","year":"2015","unstructured":"Wu P, Wu D, Li L et al (2015) PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 10:e0131403. https:\/\/doi.org\/10.1371\/journal.pone.0131403","journal-title":"PLoS One"},{"key":"2189_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11523-016-0451-8","volume":"11","author":"X Li","year":"2016","unstructured":"Li X, Li M, Lian Z et al (2016) Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis. Target Oncol 11:753\u2013761. https:\/\/doi.org\/10.1007\/s11523-016-0451-8","journal-title":"Target Oncol"},{"key":"2189_CR8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jtho.2016.04.007","volume":"11","author":"JM Sun","year":"2016","unstructured":"Sun JM, Zhou W, Choi YL et al (2016) Prognostic significance of PD-l1 in patients with non-small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol 11:1003\u20131011. https:\/\/doi.org\/10.1016\/j.jtho.2016.04.007","journal-title":"J Thorac Oncol"},{"key":"2189_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12:208\u2013222. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2228","journal-title":"J Thorac Oncol"},{"key":"2189_CR10","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13:1302\u20131311. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.013","journal-title":"J Thorac Oncol"},{"key":"2189_CR11","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-16-1821","volume":"23","author":"JC Sunshine","year":"2017","unstructured":"Sunshine JC, Nguyen PL, Kaunitz GJ et al (2017) PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Cancer Res 23:4938\u20134944. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1821","journal-title":"Clin Cancer Res"},{"key":"2189_CR12","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cam4.2110","volume":"8","author":"Y Fujisawa","year":"2019","unstructured":"Fujisawa Y, Yoshikawa S, Minagawa A et al (2019) Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med 8:2146\u20132156. https:\/\/doi.org\/10.1002\/cam4.2110","journal-title":"Cancer Med"},{"key":"2189_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/pgp.0000000000000623","volume":"39","author":"O Saglam","year":"2020","unstructured":"Saglam O, Zhou J, Wang X et al (2020) PD-L1 expression correlates with young age and CD8+ TIL density in poorly differentiated cervical squamous cell carcinoma. Int J Gynecol Pathol 39:428\u2013435. https:\/\/doi.org\/10.1097\/pgp.0000000000000623","journal-title":"Int J Gynecol Pathol"},{"key":"2189_CR14","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.7150\/jca.30573","volume":"10","author":"S Yun","year":"2019","unstructured":"Yun S, Park Y, Moon S et al (2019) Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J Cancer 10:3070\u20133078. https:\/\/doi.org\/10.7150\/jca.30573","journal-title":"J Cancer"},{"key":"2189_CR15","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K (2019) CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234:8509\u20138521. https:\/\/doi.org\/10.1002\/jcp.27782","journal-title":"J Cell Physiol"},{"key":"2189_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/modpathol.2016.210","volume":"30","author":"N Frydenlund","year":"2017","unstructured":"Frydenlund N, Leone D, Yang S et al (2017) Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Mod Pathol 30:357\u2013369. https:\/\/doi.org\/10.1038\/modpathol.2016.210","journal-title":"Mod Pathol"},{"key":"2189_CR17","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1158\/0008-5472.Can-18-0118","volume":"78","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto H, Fujieda K, Miyashita A et al (2018) Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res 78:5011\u20135022. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0118","journal-title":"Cancer Res"},{"key":"2189_CR18","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1111\/jdv.15742","volume":"33","author":"Y Nakamura","year":"2019","unstructured":"Nakamura Y, Ishitsuka Y, Tanaka R et al (2019) Acral lentiginous melanoma and mucosal melanoma expressed less programmed-death 1 ligand than cutaneous melanoma: a retrospective study of 73 Japanese melanoma patients. J Eur Acad Dermatol Venereol 33:e424\u2013e426. https:\/\/doi.org\/10.1111\/jdv.15742","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2189_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","volume":"31","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Namikawa K, Yoshino K et al (2020) Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol 31:1198\u20131206. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.031","journal-title":"Ann Oncol"},{"key":"2189_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/jco.2016.67.9258","volume":"35","author":"SP D'Angelo","year":"2017","unstructured":"D\u2019Angelo SP, Larkin J, Sosman JA et al (2017) Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35:226\u2013235. https:\/\/doi.org\/10.1200\/jco.2016.67.9258","journal-title":"J Clin Oncol"},{"key":"2189_CR21","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.30259","volume":"122","author":"AN Shoushtari","year":"2016","unstructured":"Shoushtari AN, Munhoz RR, Kuk D et al (2016) The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 122:3354\u20133362. https:\/\/doi.org\/10.1002\/cncr.30259","journal-title":"Cancer"},{"key":"2189_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1684\/ejd.2020.3846","volume":"30","author":"M Giavina-Bianchi","year":"2020","unstructured":"Giavina-Bianchi M, Giavina-Bianchi P, Sotto MN et al (2020) Nodular primary cutaneous melanoma is associated with PD-L1 expression. Eur J Dermatol 30:352\u2013357. https:\/\/doi.org\/10.1684\/ejd.2020.3846","journal-title":"Eur J Dermatol"},{"key":"2189_CR23","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00432-019-02915-1","volume":"145","author":"F Thangarajah","year":"2019","unstructured":"Thangarajah F, Morgenstern B, Pahmeyer C et al (2019) Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. J Cancer Res Clin Oncol 145:1651\u20131660. https:\/\/doi.org\/10.1007\/s00432-019-02915-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"2189_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ajd.13607","volume":"62","author":"J Kato","year":"2021","unstructured":"Kato J, Sugita S, Horimoto K et al (2021) Expression of programmed cell death ligand 1 (PD-L1) at in situ and invasive extramammary Paget\u2019s disease and literature review. Australas J Dermatol 62:412\u2013414. https:\/\/doi.org\/10.1111\/ajd.13607","journal-title":"Australas J Dermatol"},{"key":"2189_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182692","volume":"12","author":"L Gu","year":"2017","unstructured":"Gu L, Chen M, Guo D et al (2017) PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS One 12:e0182692. https:\/\/doi.org\/10.1371\/journal.pone.0182692","journal-title":"PLoS One"},{"key":"2189_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001558","volume":"8","author":"M Rozenblit","year":"2020","unstructured":"Rozenblit M, Huang R, Danziger N et al (2020) Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer 8:e001558. https:\/\/doi.org\/10.1136\/jitc-2020-001558","journal-title":"J Immunother Cancer"},{"key":"2189_CR27","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF et al (2018) Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 24:1655\u20131661. https:\/\/doi.org\/10.1038\/s41591-018-0198-0","journal-title":"Nat Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02189-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T03:30:54Z","timestamp":1658719854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02189-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02189-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}